Abcam, ab315153, Anti-Gm6A antibody [EPR25802-21] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Guanine N6-methyladenosine (Gm6A) antibody. Carrier free. Suitable for FRET, Dot and reacts with Nucleic Acid samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR25802-21,
Isotype:IgG,
Carrier free:Yes,
Applications:FRET, DotSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab315153 is the carrier-free version of
ab315152
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Gm6A also known as N6-methyladenosine (m6A) methyltransferase is an essential component of the RNA modification machinery. It plays a critical role in post-transcriptional regulation. The protein mass of Gm6A is approximately 86 kDa. It is widely expressed in mammalian cells particularly prominent in brain and liver tissues. Gm6A facilitates the methylation of adenosine residues on RNA molecules influencing RNA stability splicing and export.
Biological function summary
Gm6A functions in the regulation of RNA metabolism. As an important player in epitranscriptomics it is part of the methyltransferase complex along with METTL3 and METTL14. This complex modifies messenger RNA to control gene expression and ensure proper cellular responses to various stimuli. The modification process governed by Gm6A is essential for maintaining RNA dynamic functions involving feedback loops where altered RNA impacts protein synthesis and cell signaling pathways.
Pathways
Multiple cellular processes rely on the functions of Gm6A methylation. It's involved in the mRNA processing pathway contributing to splicing and alternative polyadenylation. Gm6A interacts with proteins like YTHDF1 and YTHDF2 which mediate mRNA translation and degradation. Through these pathways Gm6A supports cell differentiation and stress responses embedding itself in the larger network of gene expression regulation.
Gm6A regulation has implications in cancer and neurological disorders. Altered m6A methylation patterns correlate with tumorigenesis in cancers including leukemia and glioblastoma. The aberrant methylation affects proteins like FTO which is an m6A demethylase potentially driving oncogenic pathways. In neurological contexts disruptions in m6A methylation play a role in neurodevelopmental disorders with implications for proteins such as RBM15 that are involved in cognitive functions and brain development.